OncoMatch/Clinical Trials/NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Is NCT07216703 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for cervical cancer.
Treatment: Pembrolizumab · Sacituzumab Tirumotecan · Bevacizumab · Paclitaxel · Cisplatin · Carboplatin · Rescue Medications — Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) expression of combined positive score ≥1 (CPS ≥1)
Has tumor programmed cell death ligand 1 expression of combined positive score ≥1
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: other than what is specified in this protocol
Has received prior systemic anticancer therapy other than what is specified in this protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mount Sinai Comprehensive Cancer Center ( Site 6000) · Miami Beach, Florida
- TRIALS 365 ( Site 6008) · Shreveport, Louisiana
- Women's Cancer Center of Nevada ( Site 6011) · Las Vegas, Nevada
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) · New York, New York
- University of Tennessee Medical Center ( Site 6012) · Knoxville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify